EP1343515A1 - Verbindungen für die verzögerte freigabe von oral verabreichten arzneimitteln - Google Patents

Verbindungen für die verzögerte freigabe von oral verabreichten arzneimitteln

Info

Publication number
EP1343515A1
EP1343515A1 EP01979594A EP01979594A EP1343515A1 EP 1343515 A1 EP1343515 A1 EP 1343515A1 EP 01979594 A EP01979594 A EP 01979594A EP 01979594 A EP01979594 A EP 01979594A EP 1343515 A1 EP1343515 A1 EP 1343515A1
Authority
EP
European Patent Office
Prior art keywords
substituted
group
animal
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01979594A
Other languages
English (en)
French (fr)
Other versions
EP1343515A4 (de
Inventor
Mark A. Gallop
Kenneth C. Cundy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XenoPort Inc
Original Assignee
XenoPort Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XenoPort Inc filed Critical XenoPort Inc
Priority claimed from PCT/US2001/031486 external-priority patent/WO2002028411A1/en
Publication of EP1343515A1 publication Critical patent/EP1343515A1/de
Publication of EP1343515A4 publication Critical patent/EP1343515A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP01979594A 2000-10-06 2001-10-05 Verbindungen für die verzögerte freigabe von oral verabreichten arzneimitteln Withdrawn EP1343515A4 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US23875800P 2000-10-06 2000-10-06
US238758P 2000-10-06
US24980400P 2000-11-17 2000-11-17
US249804P 2000-11-17
US29764101P 2001-06-11 2001-06-11
US29759401P 2001-06-11 2001-06-11
US29765401P 2001-06-11 2001-06-11
US297641P 2001-06-11
US297594P 2001-06-11
US297654P 2001-06-11
PCT/US2001/031486 WO2002028411A1 (en) 2000-10-06 2001-10-05 Compounds for sustained release of orally delivered drugs

Publications (2)

Publication Number Publication Date
EP1343515A1 true EP1343515A1 (de) 2003-09-17
EP1343515A4 EP1343515A4 (de) 2005-08-03

Family

ID=27540106

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01979594A Withdrawn EP1343515A4 (de) 2000-10-06 2001-10-05 Verbindungen für die verzögerte freigabe von oral verabreichten arzneimitteln

Country Status (2)

Country Link
EP (1) EP1343515A4 (de)
AU (1) AU2002211538A1 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009163A2 (en) * 1999-07-30 2001-02-08 The University Court Of The University Of Glasgow Improvement of peptide transport by conjugation with bile acids
WO2002100347A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009163A2 (en) * 1999-07-30 2001-02-08 The University Court Of The University Of Glasgow Improvement of peptide transport by conjugation with bile acids
WO2002100347A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRAMER W ET AL: "Modified bile acids as carriers for peptides and drugs" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 46, no. 1-2, 5 May 1997 (1997-05-05), pages 17-30, XP004096309 ISSN: 0168-3659 *
LEE V H ET AL: "Pharmacogenomics of drug transporters: the next drug delivery challenge." ADVANCED DRUG DELIVERY REVIEWS. 1 OCT 2001, vol. 50 Suppl 1, 1 October 2001 (2001-10-01), pages S33-S40, XP002329540 ISSN: 0169-409X *
See also references of WO0228411A1 *

Also Published As

Publication number Publication date
AU2002211538A1 (en) 2002-04-15
EP1343515A4 (de) 2005-08-03

Similar Documents

Publication Publication Date Title
US20080255073A1 (en) Compounds for sustained release of orally delivered drugs
WO2002028411A1 (en) Compounds for sustained release of orally delivered drugs
US7598235B2 (en) Bile-acid conjugates for providing sustained systemic concentrations of drugs
US20020151526A1 (en) Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
US6992076B2 (en) Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US7919454B2 (en) Methods of treating using conjugates transported by a PEPT2 transporter
US7727976B2 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US20030158254A1 (en) Engineering absorption of therapeutic compounds via colonic transporters
US7183259B2 (en) Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
WO2002042414A2 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
EP1343515A1 (de) Verbindungen für die verzögerte freigabe von oral verabreichten arzneimitteln

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030404

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050620

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 47/48 B

Ipc: 7A 01N 37/18 B

Ipc: 7A 61M 36/14 B

Ipc: 7A 61K 51/00 B

Ipc: 7A 61K 47/00 B

Ipc: 7A 61K 38/00 A

17Q First examination report despatched

Effective date: 20070525

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090922